Helsen Pharma & Consulting SRL
Helsen Pharma & Consulting reported total assets of 269,729 € at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Jun 2026).
The score of Helsen Pharma & Consulting shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Helsen Pharma & Consulting's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Jun 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
Helsen Pharma & Consulting's financial analysis
- Solvency17.2%sector median: 47.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Helsen Pharma & Consulting
Helsen Pharma & Consulting's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0799.409.266
- VAT number
- BE0799409266
- Peppol
- Registered · 0208:0799409266 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Mar 2023
- Registered office
- 2440 Geel
- Latest accounts
- 2025 · filed on 19 Jun 2026
- Activity
- Fund management activities (NACE 66300)
Helsen Pharma & Consulting (SRL) has been based in Geel since 2023, active in: fund management activities. For 2025, it reports a net profit of 22,350 € and equity of 46,294 €; its revenue is not published. Its solvency stands at 17.2%, below the median of its sector (47.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Helsen Pharma & Consulting
Companies in the same business, of comparable size and area, outside its group.
- Marleen Hoste & Partners Business and other management consultancy activities De Haan · balance sheet 318,783 €
- Cafidex Business and other management consultancy activities Nieuwerkerken (Limb.) · balance sheet 244,534 €
- G-Blue Business and other management consultancy activities Sprimont · balance sheet 354,233 €
- Van Damme & Partners Business and other management consultancy activities Merelbeke · balance sheet 400,127 €
- Karuna Business and other management consultancy activities Zandhoven · balance sheet 123,853 €
- ASIT Business and other management consultancy activities Huldenberg · balance sheet 496,534 €
- Food Processing Group Business and other management consultancy activities Lommel · balance sheet 534,683 €
- Jolibar Business and other management consultancy activities Merelbeke-Melle · balance sheet 726,253 €
Frequently asked questions about Helsen Pharma & Consulting
What is the revenue of Helsen Pharma & Consulting?
Helsen Pharma & Consulting files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Helsen Pharma & Consulting?
In Belgium, the VAT number is the company number prefixed with BE: BE0799409266 for Helsen Pharma & Consulting, if the company is VAT-registered. Its company number (CBE) is 0799.409.266.
Where is the registered office of Helsen Pharma & Consulting?
According to the CBE register, the registered office of Helsen Pharma & Consulting is in 2440 Geel.
What is the equity of Helsen Pharma & Consulting?
At the close of the 2025 financial year, the equity of Helsen Pharma & Consulting amounts to 46,294 €, a solvency of 17.2% of total assets.
Who manages Helsen Pharma & Consulting?
The register lists 1 active mandates at Helsen Pharma & Consulting. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Helsen Pharma & Consulting
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →